Vilon — Research Overview | Peptide News Network

Vilon is among the simplest compounds in the entire Khavinson “bioregulator” family — a dipeptide, just two amino acids — and it is one of the oldest. It carries the family’s usual caution: a real but narrow, largely single-program literature, and a headline mechanism that is more hypothesis than established fact. It also carries one finding that needs especially careful handling — an animal lifespan result that is easy to overstate. As with its siblings, an honest overview credits what is genuinely documented while drawing a clear line at what is not.

This summary describes what the chemical record and the published literature report about Vilon — its identity, its proposed mechanism, the nature and limits of the evidence supporting it, and its regulatory status. It describes findings as they appeared in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

What Vilon Is

Vilon is a synthetic dipeptide with the sequence lysine-glutamic acid (Lys-Glu), also written KE, and cataloged in the chemical databases as lysylglutamic acid (PubChem CID 7010502). It was developed within the program led by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, derived from analysis of the thymic peptide preparation Thymalin and positioned as a thymus-associated immune bioregulator (Vilon identity and thymic origin). At two amino acids, it is one of the smallest biologically studied peptides in the family.

Proposed Mechanism

Vilon is proposed to act via a mechanism shared across the Khavinson family: rather than binding cell-surface receptors, the dipeptide is hypothesized to interact directly with chromatin and DNA, thereby influencing gene expression — here, in immune and epithelial cells. The proposed framing centers on immune modulation: normalizing the balance between cell proliferation and apoptosis and influencing the expression of genes associated with inflammation and immune cell function.

There is some reported mechanistic detail behind the hypothesis. In-vitro work describes Vilon affecting chromatin structure in cultured lymphocytes from older donors — reported as reactivation of normally ‘silent’ heterochromatin regions (Lezhava et al., chromatin reactivation (PMID 15105581)) — and a separate study examined short-peptide effects on interleukin-2 gene expression in splenocytes. Still, the direct-DNA-regulation model remains the program’s hypothesis and is not widely established in the broader molecular biology literature.

The Evidence Base — and the Lifespan Finding

Vilon’s evidence is preclinical and originates overwhelmingly from the Khavinson program. Some of it is PubMed-indexed, which puts it ahead of the thinnest members of the family, but none of it is independently replicated human-trial data.

One finding deserves careful, explicit framing because it is the one most likely to be overstated. A published mouse study reported that synthetic Vilon (L-Lys-L-Glu) inhibited the growth of spontaneous tumors and increased the lifespan of the mice (Khavinson & Anisimov, lifespan/tumor study in mice (PMID 10944717)). That is a real result — in mice, from the originating group. It is emphatically not evidence that Vilon extends human lifespan or treats or prevents cancer in people. Animal lifespan and tumor-incidence findings are a starting point for further research, not a human health claim, and the gap between the two is wide and not bridged by any human trial.

The broader limitation, stated plainly: Vilon’s research is concentrated in one program; much of it is decades old or Russian-language; independent replication is limited; and there are no registered international clinical trials demonstrating efficacy. The cell-level effects are consistently reported in that body of work, but consistency within a single program is not independent confirmation.

Findings come from cell and rodent studies; several are PubMed-indexed but program-internal.
The mouse lifespan / anti-tumor result is a real animal finding, not a human anti-aging or anti-cancer claim.
No independently replicated or registered human clinical-trial evidence of efficacy exists.

Regulatory Status

The status below reflects mid-2026 and may change; verify against current sources before relying on it. Vilon is not FDA-approved for any indication in the United States. It is sold as a research-grade compound for laboratory use only and, by its labeling, is not intended for human consumption. In some markets, these bioregulators are sold within supplement-style categories, which are regional regulatory classifications rather than evidence of efficacy. Like other Khavinson peptides, it falls outside the FDA’s 503A peptide-compounding framework and has no established clinical or compounded-access pathway in U.S. practice.

Why Vilon Appears in Research Discussions

The conceptual appeal is twofold: the family-wide idea that an ultra-short, tissue-associated peptide might act as a gene-level regulator, plus Vilon’s specific status as a striking example of “peptide minimalism” — a two-amino-acid molecule reported to have measurable immune and chromatin effects. The accurate framing remains carefully qualified: a defined dipeptide with a consistent identity, a preclinical record concentrated in one largely unreplicated program, an unproven direct-DNA mechanism, an animal lifespan finding that should not be read as a human claim, and no confirmed human-trial validation. It is a reasonable object of laboratory curiosity, not an established therapy.

For deeper reading, the indexed primary studies cited here are the best starting point. Vilon is best understood alongside the other Khavinson bioregulators — see the related Pinealon, Cortagen, Cardiogen, Cartalax, and Chonluten overviews — and the wider class is collected in our peptide research library.

A note on the evidence base: Independent, peer-reviewed evidence in English is limited; much of the available literature on Vilon originates from the originating research group (the Khavinson program) and has not been widely replicated, though some independent cell-line work exists. The citations below reflect that literature, and readers should weigh it accordingly.